Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Page 13 of 14
Jan 18, 2026Recent insights emphasize that programs which blend personalized human interaction alongside effective use of technology outperform those relying on technology alone in improving healthcare member engagement, quality outcomes, and retention.
Jan 18, 2026The COVID-19 pandemic left profound emotional and psychological scars on healthcare workers and communities. This opinion piece explores the lingering despair and calls attention to the lack of public accountability and outrage regarding the pandemic's management.
Jan 16, 2026With a substantial fund allocation, the Novo Nordisk Foundation aims to accelerate breakthrough innovations, fostering a sustainable ecosystem for biotechnology and health-related technological advances in both Denmark and the wider European landscape.
Jan 15, 2026The healthcare sector is witnessing unprecedented private equity inflows, marking a record investment milestone in 2025. However, this surge has led to heightened competition among investors for premium assets, influencing market dynamics and raising strategic considerations for future investment and growth.
Jan 14, 2026During the JPM26 conference, Sanofi's leadership revealed their tactical move to buy shares in vaccine biotech company Dynavax amidst a backdrop of short-term market downturn caused by vaccine-related political controversies. This decision reflects Sanofi’s long-term confidence in vaccine innovation and market recovery.
Jan 10, 2026With participation from prominent investors including Andreessen Horowitz and Atomico, Pomelo plans to leverage the funding to expand its care models and technologies beyond maternity services, potentially impacting women’s health more broadly.
Jan 9, 2026Aktis Oncology’s sizeable IPO reflects growing investor interest in innovative radiopharmaceutical approaches for cancer. The company’s pipeline focuses on miniprotein radioconjugates aimed at targeted radiation delivery, and it benefits from a discovery partnership with Eli Lilly.
Jan 9, 2026This potential consolidation could be one of the largest private equity-backed health tech ventures, focusing on integrating payer, provider, and data services. The outcome remains uncertain in terms of value delivery or success.
Jan 9, 2026Former New Mountain Capital executive Matt Holt explores combining five health tech startups into the 'Thoreau' platform, seeking to streamline services across payers, providers, and data. If successful, this ambitious project would rank among the largest private equity-backed ventures in health tech.
Jan 8, 2026The significant funding round by Parabilis Medicines exemplifies renewed investor interest in oncology drug development, amid a broader wave of biotech financing involving several other emerging companies this January.
Jan 8, 2026The funding round led by Parabilis highlights the strong biotech fundraising environment as several companies have attracted significant capital recently. These investments underpin ongoing efforts to develop innovative cancer treatments.
Jan 8, 2026The surge in mergers and acquisitions within obesity and diabetes therapeutics marked a major investment shift in 2025, reflecting increased market confidence in these disease areas despite broader funding challenges.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.